Results 221 to 230 of about 1,419,720 (263)

Mineralocorticoid receptor antagonists

2022
Abstract This chapter studies the use of aldosterone antagonists, also known as mineralocorticoid receptor antagonists (MRAs), in chronic heart failure (CHF). Overall, the results for aldosterone blockade in CHF due to left ventricular systolic dysfunction—now called heart failure with reduced ejection fraction (HFrEF)—have been very ...
S. Rekhraj, Ben. R. Szwejkowski, Allan D. Struthers   +2 more
openaire   +1 more source

Nonsteroidal antagonists of the mineralocorticoid receptor

Current Opinion in Nephrology and Hypertension, 2015
The broad clinical use of steroidal mineralocorticoid receptor antagonists (MRAs) is limited by the potential risk of inducing hyperkalemia when given on top of renin-angiotensin system blockade. Drug discovery campaigns have been launched aiming for the identification of nonsteroidal MRAs with an improved safety profile.
Peter, Kolkhof, Christina, Nowack, Frank, Eitner   +2 more
openaire   +2 more sources

Mineralocorticoid Receptor Antagonists for Heart Failure [PDF]

Expert Opinion on Pharmacotherapy, 2011
Although mineralocorticoid receptor (MR) antagonists are indicated in systolic heart failure, they are underprescribed in patients with appropriate indications for their prescription and often used in those in whom the evidence for probable benefit is scant.
exaly   +5 more sources

Aldosterone, Mineralocorticoid Receptor and the Metabolic Syndrome:Role of the Mineralocorticoid Receptor Antagonists

Current Vascular Pharmacology, 2012
Several lines of evidence suggest a detrimental effect of aldosterone excess on the development of metabolic alterations. Glucose metabolism derangements due to aldosterone action are frequently observed not only in patients with primary aldosteronism but also in patients with obesity. A contribution to the hyperaldosteronism observed in obese subjects
Ronconi, Vanessa, Turchi, Federica, Appolloni, Gloria, di Tizio, Valentina, BOSCARO, MARCO, Giacchetti, Gilberta   +5 more
openaire   +2 more sources

Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists

Current Hypertension Reports, 2020
Recently, nonsteroidal mineralocorticoid receptor (MR) antagonists (MRAs), which have been proposed to be called MR blockers (MRBs), have become available for clinical use, but their clinical role is unknown. We reviewed the clinical roles of MRAs and MRBs based on previous knowledge and as demonstrated in representative clinical trials.Steroidal MRAs,
Daisuke, Sueta, Eiichiro, Yamamoto, Kenichi, Tsujita   +2 more
openaire   +2 more sources

3,3-Bisaryloxindoles as mineralocorticoid receptor antagonists

Bioorganic & Medicinal Chemistry Letters, 2005
Syntheses and SAR studies of 3,3-bisaryloxindole analogues provided potent mineralocorticoid receptor (MR) antagonists that were selective over other steroid nuclear hormone receptors.
David A, Neel, Matthew L, Brown, Peter A, Lander, Timothy A, Grese, Jean M, Defauw, Robert A, Doti, Todd, Fields, Sally Ann, Kelley, Stephon, Smith, Karen M, Zimmerman, Mitchell I, Steinberg, Prabhakar K, Jadhav   +11 more
openaire   +2 more sources

Adverse Effects of Mineralocorticoid Receptor Antagonist Administration

Current Pharmaceutical Design, 2019
Background: Mineralocorticoid receptor antagonists consist of a class of drugs with pleiotropic beneficial effects in several cardiovascular diseases. However, physicians frequently overlook their use due to the adverse effects of such agents. Objectives:
Manolis S Kallistratos, Leonidas E Poulimenos, Athanasios J Manolis   +2 more
exaly   +3 more sources

Safety and Efficacy of Steroidal Mineralocorticoid Receptor Antagonists in Patients With Kidney Failure Requiring Dialysis: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

Lancet, The
Background: Mineralocorticoid receptor antagonists can prevent cardiovascular events in patients with heart failure and non-severe chronic kidney disease, but their effects in patients with kidney failure requiring dialysis are uncertain.
Michael Walsh, Martin Gallagher, PJ Devereaux   +2 more
exaly   +2 more sources

Mineralocorticoid receptor antagonists and hypertension: Is there a rationale?

Current Hypertension Reports, 2004
Accumulating evidence indicates that aldosterone is involved in cardiovascular disease by inducing inflammation in the presence of moderate amounts of salt in the diet. Spironolactone and eplerenone are the mineralocorticoid receptor (MR) antagonists currently available for the treatment of hypertension.
Olga, Gumieniak, Gordon H, Williams
openaire   +2 more sources

Mineralocorticoid Receptor Antagonists in Primary Aldosteronism

Current Pharmaceutical Design, 2019
Background:Primary aldosteronism is the most common causes of secondary hypertension. Patients suffering from this clinical syndrome have an increased cardiovascular risk and target organ damage. Mineralocorticoid receptor antagonists are the optimal pharmaceutical option for the management of such patients.Objectives:The study aimed to assess the ...
Konstantinos, Stavropoulos, Christodoulos, Papadopoulos, Konstantinos, Koutsampasopoulos, Georgios, Lales, Christos, Mitas, Michael, Doumas   +5 more
openaire   +2 more sources